Wednesday, 01 December 2021

Japan offers new treatment option for brain cancer

02 November 2021 | News

Daiichi Sankyo launches DELYTACT® Oncolytic Virus G47∆ in Japan

image credit- shutterstock

image credit- shutterstock

Japanese firm Daiichi Sankyo Company has launched DELYTACT® (teserpaturev/G47∆), an oncolytic virus developed by the company in collaboration with Professor Tomoki Todo of the Institute of Medical Science, The University of Tokyo.

DELYTACT® (teserpaturev/G47∆) is a genetically engineered oncolytic herpes simplex virus type 1 (HSV-1).

DELYTACT® received conditional and time-limited marketing approval in Japan as a regenerative medical product for treatment of malignant glioma in June 2021 based on results from a Japanese phase 2 clinical trial (investigator-initiated trial) in patients with glioblastoma (a type of malignant glioma) conducted by Dr. Todo.

For the time being, DELYTACT® will be commercially available only at hospitals that served as trial sites. Daiichi Sankyo will establish a stable supply system of the medicine as soon as possible.

Daiichi Sankyo is offering DELYTACT® as a new option for the treatment of malignant glioma and to contribute to the high unmet medical needs of patients suffering from this brain cancer.

Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account